Stmkr Posted - 3 hours ago

$TFFP Nice platform but cash runway is terrible. What is the bull scenario here? I know TFFP plans to license/find a partner for TFF-vori (won't be easy with antifungals in the pipeline). But what about TFF-tacrolimus? How are they going to fund further clinical development? has the company announced anything?

MajorBlockbuster Posted - 3 hours ago

$TFFP https://www.sec.gov/Archives/edgar/data/1733413/000121390024038232/ea0205053-424b4_tffpharma.htm

beaches911 Posted - 04/30/24

$TFFP

beaches911 Posted - 04/30/24

$TFFP Just wait a couple of months and there will be another 70% dilution.

BoudanMarketman Posted - 04/29/24

$TFFP why partner when you can buy the assets and get rid of the disaster management team in bankruptcy.

DonCorleone77 Posted - 04/29/24

$TFFP TFF Pharmaceuticals 1.67M share Secondary priced at $2.88 H.C. Wainwright is acting as sole book running manager for the offering.

Stock_Titan Posted - 04/29/24

$TFFP TFF Pharmaceuticals Announces Pricing of $4.8 Million Public Offering https://www.stocktitan.net/news/TFFP/tff-pharmaceuticals-announces-pricing-of-4-8-million-public-kjdb89dikvni.html

Stock_Titan Posted - 04/29/24

$TFFP TFF Pharmaceuticals Makes Available Phase 2 Data from Tacrolimus Inhalation Powder (TFF TAC) for the Prevention of Lung Transplant Rejection Presented at the Recent ISHLT Annual Meeting https://www.stocktitan.net/news/TFFP/tff-pharmaceuticals-makes-available-phase-2-data-from-tacrolimus-o7jiehufz9xh.html

firewire11 Posted - 04/22/24

$TFFP ok fess up. Who dumped their tffp into inmb today ?

DonCorleone77 Posted - 04/18/24

$TFFP TFF Pharmaceuticals files to sell 147,500 shares of common stock for holders

Logic102 Posted - 04/18/24

$TFFP Market Crap down down down to 0

firewire11 Posted - 04/16/24

$TFFP market cap 8 mil ... Really?

beaches911 Posted - 04/16/24

$TFFP

SteelWheels Posted - 04/15/24

$TFFP Effn Garbage!!!

5by5 Posted - 04/15/24

$TFFP Added today... is it Q3 yet? Looking forward to it.

OpenOutcrier Posted - 04/15/24

$TFFP (+7.8% pre) TFF Pharmaceuticals (TFFP) Announces Additional Positive Data from the Tacrolimus Inhalation Powder Phase 2 Trial - SI https://ooc.bz/l/30343

DonCorleone77 Posted - 04/15/24

$TFFP TFF Pharmaceuticals announces data from TFF TAC Phase 2 trial TFF Pharmaceuticals announced additional data from the ongoing Phase 2 study which is evaluating Tacrolimus Inhalation Powder for the prevention of organ rejection in lung transplant recipients. These new data were presented by Professor Gregory Snell, the lead Principal Investigator of the TFF TAC Phase 2 study, in an oral presentation at the International Society for Heart and Lung Transplantation 44th Annual Meeting at a late breaking clinical science abstract session, on April 13, 2024, in Prague, Czech Republic. TFF TAC - updated Phase 2 data post ISHLT 2024 Meeting: The ongoing Phase 2 trial of TFF TAC is an open-label study in lung transplant patients who require reduced tacrolimus blood levels due to kidney toxicity. Part A of the trial is a 12-week treatment period, and Part B is an optional safety extension period. Trial endpoints include safety, tolerability, kidney function, and acute allograft rejection. In March 2024, the Company announced updated data from the first eight patients enrolled in the trial. Today, the Company announced additional data from the trial, including new gene expression data assessing molecular markers of acute rejection, that were presented by Professor Gregory Snell at the ISHLT 2024 Annual Meeting on April 13, 2024. Updated Efficacy: Successful transition of eight of eight patients from oral Tacrolimus to TFF TAC; No evidence of acute rejection: No signs and symptoms suggestive of acute rejection; No use of pulse corticosteroids to treat acute rejection; No deterioration in spirometry suggestive of acute rejection; No chest x-ray findings suggestive of acute rejection; No gene expression evidence of rejection in 4/4 patients with available gene expression data on endobronchial biopsies: Rejection-related genes normalized on TFF TAC in 3/3 patients with abnormal expression of rejection-related genes at baseline while on oral tacrolimus; Rejection-related genes remained normal on TFF TAC in one patient with normal expression of rejection related genes at baseline. 4/4 patients who completed Part A chose to remain on TFF TAC and proceeded to Part B. Updated Safety: No mortality; No TFF TAC discontinuation due to an AE; Majority of TEAEs were Grade 2 or lower in severity; Maintenance of kidney function . Based on these results, TFF Pharmaceuticals plans to open an IND in the US to explore the use of TFF TAC early post-transplant in preparation for a registrational trial.

Stock_Titan Posted - 04/15/24

$TFFP TFF Pharmaceuticals Announces Additional Positive Data from the Tacrolimus Inhalation Powder (TFF TAC) Phase 2 Trial Following Oral Presentation at the ISHLT 44th Annual Late Breaking Clinical Science Abstract Sessions https://www.stocktitan.net/news/TFFP/tff-pharmaceuticals-announces-additional-positive-data-from-the-ey1pytgn85tm.html

MajorBlockbuster Posted - 04/11/24

$TFFP the great opportunity awaits: https://x.com/yaireinhorn/status/1778458368711000404?s=46

beaches911 Posted - 04/10/24

$TFFP All shareholders please bend over, Harlan is about to do a deal again

Logic102 Posted - 04/09/24

$TFFP No transparency and plenty of past lies. I am now totally out of this POS company. The science looked promising at one point, but lies are lies and crap management is crap management.

firewire11 Posted - 04/08/24

$TFFP can the dilution be the catalyst if we don't know the terms? A late April's Fool joke perhaps.

DonCorleone77 Posted - 04/08/24

$TFFP TFF Pharmaceuticals files to sell common stock, warrants, no amount given

WizeKing44 Posted - 04/07/24

$TFFP Data incoming

Rungreen Posted - 04/06/24

$TFFP Company just continues to burn shareholders money!

MajorBlockbuster Posted - 04/05/24

$TFFP anyone see the path here? Thanks.

DonCorleone77 Posted - 04/04/24

$TFFP TFF Pharmaceuticals price target lowered to $13 from $25 at JonesResearch JonesResearch analyst Justin Walsh lowered the firm's price target on TFF Pharmaceuticals to $13 from $25 and keeps a Buy rating on the shares following the Q4 report. While the results for both assets were encouraging, TFF is focusing resources on advancing TFF TAC for the prevention of acute rejection in lung transplant and planning on finding strategic alternatives to advance TFF VORI, the analyst tells investors in a research note. As such, the firm removed potential revenues for TFF VORI from the model.

SteelWheels Posted - 04/03/24

$TFFP Another Flop pick by TW Research . Is it a Paid subscription ?

laste_rounde Posted - 04/02/24

$TFFP Got a feeling another crap raise is in our future.

DavidStetson Posted - 04/02/24

$TFFP Great tech that needs $$$